Skip to page body Patient Care Survivorship Research Cancer Types News Giving Community Partners Clinical Trials
UCLA's Jonsson Comprehensive Cancer Center
Take the Jonsson Cancer Center Site Survey

Clinical Research Unit (CRU)

Director: Meghan Brennan, R.N., M.S.N., O.N.P. 

Medical Director: Sara Hurvitz, M.D.

Location:
10945 Le Conte Avenue, Suite 3360
University of California, Los Angeles
Los Angeles, CA 90095-7077

Telephone: (310) 794-6500

Fax: (310) 794-5517

E-mail: mbbrennan@mednet.ucla.edu

Services:

  • Administration of clinical studies by stable, well-trained core staff of clinical research nurses and data managers
  • Consultation provided by senior clinical research faculty for new and/or junior investigators developing clinical research protocols
  • Uniform scientific and quality assurance review of protocols and assurance of uniform compliance with federal guidelines for investigational drug use
  • Coordination and expansion of access to therapeutic clinical trials in all oncology disciplines within the UCLA's Jonsson Comprehensive Cancer Center.

Dr. Jackie Casillas and patient

Operating Policies:
Initial requests for resources from the CRU are made to the administrative director by those intending to use the resource. The director may recommend CRU resource allocation after review of new or junior protocols. The administrative director will determine the level of staff support required for the study. Priority will be given to translational/institutional studies, followed by cooperative groups, followed by industry-sponsored but under-funded innovative research. Factors used to determine the type and percent of full-time employee allocation for successful study conduct include the type of study and requisite requirements; the complexity of the study (i.e., complicated multistep vs. simple treatment methods); and the level of staff involvement (i.e., simple coordination of a study that is already designed study vs. assistance with protocol design and development), case report form formatting, informed consent development and IRB submission.

Last updated: 5/20/2013 1:30:35 PM